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Abstract—Several RGD peptidomimetics have been prepared, in a convergent way, from the common ortho-amino-
tyrosine template (O-substituted with an anchorage-arm or a methyl group, and aN-substituted with a fluorine tag for
XPS analysis), and various o-aminoacid derivatives. The most flexible compounds have shown a biological activity
similar to that of the peptide reference (RGDS) in the platelet aggregation test. The compound 16a could be fitted (by
modelisation) with DMP 728 and c(RGDfV), two cyclic peptides that are good ligands of integrins. The compound 16b
has been covalently fixed on the surface of a poly(ethylene terephthalate) membrane used as support for mammalian
cell cultivation. # 1998 Elsevier Science Ltd. All rights reserved.
Introduction
The use of synthetic polymers in medical engineering
and biotechnological applications has increased con-
siderably in recent years.1,2 For instance, polymer
membranes are developed as supports for in vitro culti-
vations of mammalian cells used as models of biological
barriers to investigate transport of nutrients or phar-
macological agents.3–5 Our interest in this field led us to
perform surface modifications of the supports in view to
improve the cellular adhesion and growth.6 A first
approach consisted in the introduction of functional
motifs susceptible to increase the surface hydrophilicity
and charge.7–13 The chemically modified surfaces were
further biocompatibilized by the covalent coupling of
extracellular matrix (ECM) proteins.6,14 Our current
purpose is to replace proteins by stable synthetic biologi-
cal signals that would similarly promote cell anchorage.
Accordingly, our active biocompatibilization strategy of
polymeric substrates relies on the covalent fixation of
small molecules acting as integrin ligands onto the
material surface.
Integrins15 are heterodimeric transmembrane glyco-
proteins involved in cell–cell and cell–matrix inter-
actions;16 these cell surface receptors interact with the
cytoskeleton and play a crucial role in the signal trans-
duction processes.17 Most of integrins bind to adhesive
proteins displaying the Arg-Gly-Asp (RGD) sequence.18
Platelets aggregation is mediated by the aIIbb3 integrin,
which natural ligand is the blood protein fibrinogen.19
The related integrin avb3 of endothelial cells has been
recognized as an important mediator of cellular adhesion
and migration in the angiogenesis process;20 in this case,
the natural ligand is the ECM protein vitronectin. A lot
of flexible linear peptides containing the RGD sequence
bind to integrins, but non specifically.21 On the other
hand, cyclic RGD peptides appear more selective
towards either aIIbb3 or avb3 integrins.22
Over the last 10 years, peptidomimetics23–25 of the RGD
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mainly in the field of orally available anticoagulants
(aIIbb3 antagonists) for the treatment of thrombo-
embolic diseases.26 Very recently, the search of avb3
antagonists has emerged in order to treat cancers27 and
other disorders in which neovascularization plays a cri-
tical role.28
We planned to functionalize our cell culture substrates
with RGD peptidomimetics. In the previous literature,
the grafting of RGD peptides was reported to sig-
nificantly improve the cellular adhesion on various
polymeric supports.29–31 However the eect of non-
peptide mimics was never considered, though such syn-
thetic signals should be more stable under biological
fluids, storage and sterilization conditions.
In this paper we report the preparation of several RGD
peptidomimetics based on the ortho-amino-tyrosine
template, and their evaluation in the classical platelet
aggregation test. One molecule (16b) equipped with an
anchorage-arm has been covalently fixed on a poly
(ethylene terephthalate) (PET) microporous membrane
used as cell cultivation support.
Results and Discussion
Synthesis
Several series of RGD peptidomimetics based on var-
ious rigid scaolds32,33 have been proposed as anti-
platelet agents; for instance, molecules were constructed
from benzodiazepine,34 isoquinolone,35 isoxazoline,36
pyrazolopiperazinone,37 or 3-(hydroxymethyl) benz-
amide38 moieties. The situation appears totally dierent
in the case of RGD mimics designed to promote adhe-
sion phenomena; to our knowledge, only four types of
molecules have been very recently disclosed, based on p-
hydroxybenzamide,27 piperazine,39 carbohydrate,40 or
benzodiazepine27,41 templates.
When starting this work, without reliable guide in hand,
we decided to examine relatively flexible structures
derived from (l)-tyrosine. The utilization of this tem-
plate has been well exemplified by the Merck’s scien-
tists;42,43 one compound (Aggrastat2, MK-383) is in
phase III clinical trials.44 The advantages of the tyrosine
template and the designed structural features of our
RGD peptidomimetics are summarized in the Figure 1:
(a) the aromatic template is commercially available and
already equipped with the first arm mimicking the d
(Asp) residue; (b) the a-amino function, that has to be
masked with a lipophilic group,43 can be advanta-
geously used for the fixation of a fluorine tag in view of
the X-ray photoelectron spectroscopic (XPS) analysis of
the final polymer substrates;45,46 (c) the aromatic
hydroxyl function can be used to anchor a second arm
needed for immobilizing the molecule onto polymer
substrates; (d) nitration of the aromatic ring, followed
by reduction, oers the anchorage point of the third
arm mimicking the R (Arg) residue; the distance separ-
ating the acidic and basic residues of the pharmaco-
phore should be within 10–20 A˚.27,43,47
The N-trifluoroacetyl group was initially chosen as
fluorine tag for the XPS analysis of the surface modified
polymer membranes. Therefore, in our synthetic plan,
we have avoided using protective groups removable
under basic conditions that could cleave our spectro-
scopic label; accordingly, we played exclusively with the
classical tertio-butyl (tBu), tertio-butoxycarbonyl (Boc),
and benzyloxycarbonyl (Cbz) groups.
(l)-Tyrosine tertio-butylester 1 was reacted with neat
trifluoroacetic anhydride to give N-trifluoroacetyl-(l)-
tyrosine tertio-butylester. This intermediate was directly
treated with a solution of nitric acid in acetic acid at low
temperature to furnish the mono-nitration product 2
isolated by column-chromatography (Scheme 1).
For chemoselectivity reasons, the O-alkylation of the
phenol ring has to be performed before the reduction of
the nitro group, and the subsequent functionalization of
the resulting aniline. This Williamson reaction, planned
to introduce the anchorage-arm for immobilization onto
polymer membranes, was first examined with methyl-
iodide. Thus, 2 was reacted with methyliodide, in
refluxing acetonitrile, in the presence of powdered
potassium carbonate and a crown ether as catalyst. The
product 3a, contaminated with a small amount of N-
methylation product of the trifluoroacetamide residue,
was purified by preparative medium pressure liquid
chromatography (MPLC) in 72% yield. TheN-protected
anchorage-arm, N-(Boc)-3-bromopropylamine, could
be similarly coupled to 2, giving 3b in 78% yield after
purification (Scheme 1).
The aromatic ring functionalization with various arms
mimicking the basic residue of Arg was systematically
Figure 1. The tyrosine (X=H) template and its arrangement.
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investigated, using the precursor 3a in which the
anchorage-arm is replaced with a simple methyl group.
Reduction of 3a by catalytic hydrogenation over plati-
nium oxide furnished the key-intermediate aniline 4a
which was directly used without purification. The reac-
tivity of this aniline in the peptide coupling reaction was
examined, under various experimental conditions, using
N-(Cbz)-5-aminovaleric acid as partner. Low yields of the




fluorophosphate (HBTU). The best results were obtained
when preforming the acid chloride with thionyl chloride
or 1-chloro-N,N, 2-trimethylpropenylamine;48 reaction
of N-(Cbz)-5-aminovaleryl chloride with 4a and tri-
ethylamine in dichloromethane at room temperature
gave 45% yield of the coupling product 5a after pur-
ification by column-chromatography. This strategy was
thus selected for the coupling of N-(Cbz)-6-amino-
caproic acid, N-(Cbz)-isonipecotic acid and N-(Cbz)-
nipecotic acid. Reaction of the corresponding pre-
formed acid chlorides with 4a led, respectively, to the
anilides 6a, 7a, and 8a in 35–55% yields (Scheme 1).
Hydrogenolysis of the Cbz protective group of 5a gave
the free amine 11a (tBu ester) which was submitted to
various guanidylation conditions. Unfortunately, all
attempts to react 11a with unprotected guanidylation
reagents (i.e. aminoiminomethane sulfonic acid49 and
1H-pyrazole-1-carboxamidine)50 and with the protected
reagent 17, N,N0-ditertio-butoxycarbonyl-3,5-dimethyl-
pyrazole-1-carboxamidine,51 failed. Therefore, we con-
sidered a more convergent route towards 9a (or 15a)
and 10a (or 16a), using N-guanidyl-aminoacid deriva-
tives as partners in the peptide coupling with the aniline
4a. The required acid chlorides 20 were obtained
according to the Scheme 2.
Scheme 1. Synthesis of peptidomimetics (first family). Reagents and conditons: (i) (CF3CO)2O, 0
C, 2 h; (ii) HNO3-HOAc, 10 C, 1 h;
(iii) a. CH3I, CH3CN, K2CO3, reflux, 48 h: b. BocNH-(CH2)3-Br, CH3CN, K2CO3, reflux, 24 h; (iv) H2, PtO2, EtOH, 4–12h, 20
C; (v)
acid chloride, pyridine, CH2Cl2, 17 h, 20
C; then column chromatography; (vi) Pd-C, EtOAc, 20 C, 18 h; (vii) CF3CO2H, 2 h, 20 C.
T. Boxus et al./Bioorg. Med. Chem. 6 (1998) 1577–1595 1579
5-Aminovaleric acid (a, n=4) and 6-aminocaproic acid
(b, n=5) were esterified with benzyl alcohol under stan-
dard conditions (18a,b), then reacted with N,N0-ditertio-
butoxycarbonyl-3,5-dimethylpyrazole-1-carboxamidine
1751 and triethylamine in dichloromethane. After pre-
parative MPLC, compounds 19a,b were quantitatively
obtained. Cleavage of the benzyl ester by hydro-
genolysis, followed by reaction with thionyl chloride
gave the acid chlorides 20a,b, which were not purified
(Scheme 2). Reaction of 20b (n=5) with the aniline key-
intermediate 4a in the presence of pyridine furnished the
coupling product 10a in 35% yield after purification by
column-chromatography (Scheme 1). The lower homo-
logue 9a could not be obtained by similarly treating 4a
with the valeric derivative 20a (n=4); in the presence of
pyridine, the acid chloride 20a cyclized intramolecularly
very rapidly (21, Scheme 2). Thus, in our hands, the
peptidomimetic 15a (after deprotection of 9a) was not
accessible. Treatment of 10a with trifluoroacetic acid
produced the fully deprotected guanidyl derivative 16a.
N-Deprotection of the aminocaproic derivative 6a and
(iso)nipecotic derivatives 7a and 8a by hydrogenolysis,
followed by treatment with trifluoroacetic acid to cleave
the tertio-butyl ester, gave the unprotected compounds
12a, 13a and 14a, respectively (Scheme 1).
All the compounds 6–8, 10, 12–14, and 16 were fully
characterized by the usual spectroscopic methods (see
Experimental). The typical features in the 1H NMR
spectra of the tested compounds (unprotected deriva-
tives in D2O) are as follows: (a) the three aromatic pro-
tons of the tyrosine backbone give respectively a fine
doublet at 7.3–7.5 d (J  2Hz), a doublet of doublet at
7.1–7.2 d (J  2Hz and 8.7Hz) and a doublet at 7.0–7.1
d (J  8.7Hz); (b) the proton of the tyrosine a-CH
group is a doublet of doublet at 4.6–4.8 d (J  5 and
9.5Hz); (c) the protons of the tyrosine b-CH2 group
appear to be non-equivalent, giving a ABX pattern
centred at 2.95–3.00 d and 3.25–3.30 d (JAB  14Hz).
In the 13C NMR spectra (D2O), (a) the carbon atom of
the CF3 XPS tag is visible at 118 ppm (Q); (b) the three
substituted carbon atoms of the tyrosine aromatic ring
give lines at 153 ppm, 131 ppm and 127 ppm, corre-
sponding to carbons linked to oxygen, nitrogen and
carbon respectively; (c) the a and b carbons of the ali-
phatic tyrosine chain appear at 57 ppm and 38 ppm,
respectively.
In another set of experiments, we considered the meta-
trifluoromethyl-benzenesulfonyl group (XPS tag) for
masking the a-amino function of the tyrosine template.
Due to the high acidity of the sulfonamide proton, the
presence of this function is not compatible with the
phenol ring etherification under the Williamson condi-
tions. Accordingly, the sulfonylation of the a-amino
function was performed after the tyrosine O-alkylation
step. Thus, compound 3a (see Scheme 1) was submitted
Scheme 2. Synthesis of acid chlorides. Reagents and condi-
tions: (i) PhCH2OH, pTos-OH, benzene, reflux, 3 h; (ii) Et3N,
CH2Cl2, 20 h, 20
C; (iii) H2, Pd-C, EtOH:EtOAc (1:1), 18 h,
20 C; (iv) SOCl2, CH2Cl2, 1 h, 30min, reflux; (v) pridine,
CH2Cl2, 20
C.
Scheme 3. Synthesis of peptidomimetics (second family).
Reagents and conditions: (i) K2CO3, MeOH:H2O (1:1), 17 h,
20 C; (ii) Et3N, CH2Cl2, 20 h, 20 C; (iii) H2, PtO2, MeOH,
17 h 20 C; (iv) acid chloride, pyridine, CH2Cl2, 20 h, 20 C;
then column chromatography; (v) H2, Pd-C, EtOH:EtOAc
(1:1), 18 h, 20 C; (vi) CF3CO2H, 2 h 30min, 20 C.
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to basic hydrolysis to furnish the free amine 22 which
was directly treated with meta-trifluoromethyl-benzene-
sulfonyl chloride and triethylamine; the sulfonamide 23
was purified by flash-chromatography with medium
yields (Scheme 3). Reduction of the aromatic nitro
function by hydrogenation over platinium oxide gave
the aniline key-intermediate 24. This aniline was cou-
pled with N-(Cbz)-6-aminocaproyl chloride and with
(N,N0-diterbutoxycarbonyl)-6-guanidino-caproyl chlor-
ide 20b as previously described; the corresponding ani-
lides 25 and 26 were obtained in 48% and 24% yield
after flash-chromatography. The final deprotections
were realized by hydrogenolysis followed by treatment
with trifluoroacetic acid to give 27, and by treatment
with trifluoroacetic acid to give 28 (Scheme 3). The
NMR characteristics of compounds 25–28 are similar
to those of the previous series bearing the trifluoro-
acetamide group (see Experimental): the proton of the
a-CH group gives a doublet of doublet at 4 d; the carbon
of the CF3 XPS tag is visible at 124 ppm (Q).
At last, we prepared a peptidomimetic fully equipped
for the anchorage onto polymer substrates. Reduction
of the aromatic nitro function of compound 3b (bear-
ing the N-protected aminopropyl arm) by catalytic
hydrogenation over platinium oxide gave the key-
intermediate aniline 4b (Scheme 1). Coupling with the
N-protected 6-guanidino-caproyl chloride 20b in the
presence of pyridine furnished the anilide 10b in 51%
yield after flash-chromatography. Complete deprotec-
tion of the ester, guanidino and amino functions was
realized, as usual, by treatment with trifluoroacetic acid
at room temperature; compound 16b was quantitatively
recovered (Scheme 1). In the 1H NMR spectrum, the
three methylene protons of the anchorage-arm give
multiplets at 2.13 d, 3.16 d and 4.16 d; the corresponding
13C NMR lines are found at 28.9 ppm, 39.6 ppm and
68.5 ppm.
Biological evaluation (in solution)
The in vitro activity of the compounds listed in Table 1
was assayed in a standard test of platelet aggregation
inhibition.52 Human platelet rich plasma (PRP) was
freshly prepared and platelet aggregation was measured
by recording the velocity of light transmission change
with an aggregometer. Serial dilutions of the inhibitors
were added, and aggregation was induced by addition of
adenosine diphosphate (ADP). Inhibition of platelet
aggregation was determined by comparison of light
transmittance values for the control (absence of inhi-
bitor) and the samples. The IC50 was determined as the
concentration necessary to inhibit the change in light
transmittance by 50%. We used the tetrapeptide RGDS
(Arg-Gly-Asp-Ser) as active reference compound: it
inhibits ADP-mediated platelet aggregation with a IC50
value of about 100mM.
We found that the 6-guanidino- (entries 1–3) and the 6-
aminocaproic derivatives (entry 5) are inhibitors, while
Table 1. Biological evaluation in solution
Molecules
Entry Compound IC50 (mM) (reference)a
1 COCF3 Me 16a 465 (129)
2 COCF3 16b 320 (68)
3 SO2PhCF3 Me 28 85 (68)
4 COCF3 Me 12a unsoluble
5 SO2PhCF3 Me 27 125 (100)
6 COCF3 Me 13a >1000
7 COCF3 Me 14a >1000
aIC50 value (mM) of the RGDS tetrapeptide (Arg-Gly-Asp-Ser).
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the (iso)nipecotic derivatives are inactive (entries 6 and
7). In the more active compounds, the a-amino function
of the tyrosine template was masked with a hydrophobic
arylsulfonyl group (entries 3 and 5). The presence of the
anchorage-arm (for surface immobilization) did not
perturb the activity (entry 2). The levels of activities
were similar to that of the reference peptide (RGDS).
The flexible RGDS tetrapeptide can adopt many con-
formations allowing its binding to many integrins,18,21
even though with moderate anity. We could expect a
similar behaviour in the case of the flexible peptido-
mimetic 16b, for which we have recorded a significant
anity toward the aIIbb3 integrin (fibrinogen receptor).
The same level of activity toward the avb3 integrin
(vitronectin receptor) should be sucient to promote
cell adhesion after immobilization of 16b on the surface
of culture substrates.
Modelisation
Two cyclic RGD peptides have been chosen as reference
compounds in view to evaluate the conformational
arrangement of the selected peptidomimetic 16a
(anchorage-arm replaced with a methyl group). The
DMP 728 (Fig. 2) is a potent and selective aIIbb3 integ-
rin antagonist,53,54 while the cyclo (Arg-Gly-Asp-D-
Phe-Val) (c[RGDfV]) is a potent and selective avb3
integrin antagonist (Fig. 3).55,56
Figure 3. Cyclopeptide c(RGDfV).
Figure 4. Peptidomimetic 16a.Figure 2. Cyclopeptide DMP728.
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The references and compound 16a (Fig. 4) were fully
optimized at the approximate quantum chemistry level
AM1; the molecules were studied as isolated neutral
entities, and not as zwitterionic forms, in order to avoid
internal self-folded conformations.
As previously pointed out in the literature,27,41 the
overall length of c[RGDfV] is shorter comparatively to
the aIIbb3 ligands, such as DMP 728. Indeed, the structure
is stabilized by two hydrogen-bonds between the
C=O. . .N-H group of Gly and the adjacent amide
bonds (distances of 2.216 A˚ and 2.568 A˚, respectively)
(Fig. 3). With its flexible side-chains, the potential
ligand 16a displays terminal functions that can be fairly
fitted onto the corresponding carboxyl- and guanidyl
groups of both references (Figs 5 and 6).
Surface chemistry
Poly(ethylene terephthalate) (PET) is a synthetic aro-
matic polyester widely used as a biomaterial for making
non-resorbable sutures, or performing prosthetic repla-
cements in orthopedic surgery (tendons, ligaments,
facial implants). Actually, the most successful medical
applications of PET are in the area of cardiovascular
surgery, including prosthetic heart valves and vascular
grafts of large to medium diameter (Dacron).1,2 Mem-
branes made from PET films are also appropriate sub-
strates for cultivating mammalian cells.4,6 In our
laboratory, we use microporous membranes obtained by
a track-etching process which allows the preparation of
‘capillary-pore’ membranes57 with very uniform, nearly
perfectly round cylindrical pores. Such membranes are
made from homogeneous 10–20 mm thick polymer film
precursors in two steps, consisting of bombardment
with heavy ions (Ar+9) accelerated in a cyclotron, fol-
lowed by immersion into an appropriate solution of
reagents which preferentially etches the tracks, leading
to the creation of pores.58 The etching treatment of the
PET creates functionalities (chain-endings) on the
membrane open surface that could be used for immobi-
lizing molecules of interest.
The surface displayed functions of PET membranes are
carboxyl- and hydroxyl end-groups (Scheme 4). We
have already demonstrated that the amount of carboxyl
groups could be significantly increased by a surface
oxidative treatment (KMnO4 in 1.2N H2SO4) which
transforms native hydroxyl chain-ends into new car-
boxyl endings7,9; the resulting membrane was called
PET-CO2H (Scheme 4).
The surface reactivity of the PET-CO2H membrane was
assayed by the covalent coupling of 3H-lysine followed
by liquid scintillation counting (LSC) of the sample
associated radioactivity.7,9 For that purpose, the labeling
reaction was conducted under mild conditions (water
solution, near the physiological pH, room temperature)
mimicking at best the conditions to be encountered in the
covalent coupling of the peptidomimetic molecule 16b.
Thus, the PET membrane was activated by treatment
with water soluble carbodiimide (0.1%WSC, 1 h, 20 C,
pH 3.5) and then incubated with 3H-lysine (10ÿ3M
solution, 2 h, 20 C, pH 8); we found a value of about
35 pmol/cm2 (open surface) of fixed label (corrected
value, obtained by subtracting the adsorption contribu-
tion, see Experimental). From a previously established
model of the PET surface7, we calculated that this value
corresponds to the functionalization of about 1.2% of
the monomer units (see Experimental).
Figure 5. Superposition of 16a and DMP728. Figure 6. Superposition of 16a and c(RGDfV).
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The RGD peptidomimetic 16b was similarly coupled to
the PET-CO2H membrane activated by the pre-treat-
ment with WSC (Scheme 4). A blank sample was pre-
pared by immersing a non-activated PET-CO2H
membrane into the solution of 16b in phosphate buer
(0.062%, or  10ÿ3M). The X-ray photoelectron spec-
troscopy (XPS) of the blank sample did not show the
presence of fluorine atoms on the surface (thus, no
detectable adsorption). However, the activated mem-
brane fixed (most probably by covalent grafting) the
RGD peptidomimetic as revealed by the presence of
0.24% of fluorine atoms (XPS analysis) in the atomic
composition of the sample surface (sampling depth of
about 50 A˚). From the experimental F/C  100 atomic
ratio of 0.339, we calculated (see Experimental) that
about 1.1% of the surface monomer units have fixed the
biological signal. This value is in good agreement with
the theoretical value based on the surface radiolabeling
assay (1.2%). According to Massia and Hubbell,59,60 a
surface concentration of about 10 fmol/cm2 of grafted
natural peptides is large enough to improve the cell-
adhesive properties of a biomaterial. Thus our PET
substrate, displaying about 1% of synthetic ‘RGD-like’
signals (i.e. about 30 pmol/cm2) should be a good can-
didate to promote the adhesion of anchorage-dependent
cells.
Conclusion
Several RGD peptidomimetics have been constructed
from the ortho-amino-tyrosine template. The synthetic
strategy allowed to equip the structures with an anchorage-
arm and a fluorine tag, as required for the surface
immoblilization on polymer substrates, and the sub-
sequent quantification of the amount of fixed biological
signals by X-ray photoelectron spectroscopy.
The most flexible molecule 16 has been selected for
coupling on the poly(ethylene terephthalate) membrane
currently used as cell culture support. In solution, 16a,b
exhibited moderate activities, in the platelet aggregation
test, that range the compounds at the level of the tetra-
peptide RGDS; the presence of an anchorage-arm did
Scheme 4. Covalent coupling of 16a onto the PET membrane surface.
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not perturb the biological response. The structure 16a
could be fairly fitted with two cyclic RGD peptides
which are representative ligands of the fibrogen- and
vitronectin receptors, respectively.
Using the wet-chemistry technique, we enriched the PET
membrane surface with carboxyl functions. Their acti-
vation with WSC allowed to fix the peptidomimetic 16b
in good yield, as controlled by XPS: almost all the
reactive CO2H chain-endings assayed by radiolabeling
and LSC have quenched the biological signal.
To our knowledge, the present work is the first report
dealing with the covalent coupling of RGD peptidomi-
metics on the surface of PET membrane. The perfor-
mances of such a modified support are currently




The reagents (analytical grade) were purchased from
Acros, Aldrich, or Fluka. The solvents were distilled,
after drying as follows: acetonitrile, dichloromethane,
dimethoxyethane, triethylamine and pyridine, over
calcium hydride; tetrahydrofurane, over sodium; acetone,
over drierite.
The thin-layer chromatographies were carried out on
silica gel 60 plates F254 (Merck, 0.2mm thick); visuali-
zation was eected with UV light, iodine vapor, a spray
of ninhydrin in ethanol or a spray of potassium
permanganate (3 g) and potassium carbonate (20 g) in
aqueous acetic acid (1%, 300mL). The column-
chromatographies (under normal pressure) were carried
out with Merck silica gel 60 of 70–230 mesh ASTM, and
the flash-chromatographies, with Merck silica gel 60 of
230–400 mesh ASTM. The MPLC purifications were
realized on a Prochrom equipment, with silica gel of 400
mesh ASTM, under a pressure of 40 bar and a flow of
160mL/min.
The melting points were determined with an Electro-
thermal microscope and are uncorrected. The rotations
( 0.1) were determined on a Perkin–Elmer 241 MC
polarimeter. The IR spectra were taken with a Perkin–
Elmer 600 instrument or with a Bio-Rad FTS 135
instrument, and calibrated with polystyrene (1601 cmÿ1).
The 1H and 13C NMR spectra were recorded on Varian
Gemini 300 (at 300MHz for proton and 75MHz for
carbon), or Bruker AM-500 spectrometers (at 500MHz
for proton and 125MHz for carbon); the chemical shifts
are reported in ppm (d) downfield from tetramethyl-
silane (internal standard), or sodium 2,2-dimethyl-2-
silapentane-5-sulfonate (DSS) for the spectra recorded
in D2O. The atom numbering used for the description of
the spectra is shown in the Figure 7; the attributions
were established by selective decoupling experiments.
The mass spectra were obtained on a Finnigan-MAT
TSQ-70 instrument at 70 eV (electronic impact (EI)
mode), or with a Xenon ION TECH 8KV (fast atom
bombardment (FAB) mode). The microanalyses were
performed at the Christopher Ingold Laboratories of the
University College, London. The HRMS were performed
at the University of Lie`ge (Belgium) on a VG-AutoSpec-Q
equipment (Fisons Instruments, Manchester).
N-(Trifluoroacetyl)-ortho-nitro-l-tyrosine terbutylester (2).
l-Tyrosine t-butylester 1 (478mg, 2.013mmol) was
Figure 7. Atoms numbering used in the NMR spectra description.
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dissolved, at 0 C, in trifluoroacetic anhydride (1.5mL,
2.23 g, 10.6mmol, 5.27 equiv). After 30min of stirring at
room temperature, the mixture was concentrated under
vacuum. The residue was dissolved in acetic acid (15mL)
and treated with concentrated nitric acid (115 mL,
2.4mmol, 1.2 equiv) diluted in acetic acid (15mL); the
solution of HNO3 was added dropwise, and the mixture
was maintained at 10–14 C during the addition. After
75min of reaction (TLC control), the crude mixture
was poured onto ice (400 g). The yellow precipitate was
filtered o. The aqueous phase was extracted with ethyl
acetate (4150mL). The organic phases were dried over
MgSO4, concentrated under vacuum and purified by
column chromatography on silica gel, with CH2Cl2 as
eluent, to give 0.307 g (yield: 41%) of 2: Rf=0.6; mp
85.4–87.6 C; IR (KBr) n 3358, 1755, 1709, 1550,
1161 cmÿ1; 1H NMR (CDCl3, 500MHz) d 1.48 (s, 9H,
H-b), 3.13 (dd, J=5.2 and 14.2Hz, 1H, H-7), 3.25 (dd,
J=5.9 and 14.2Hz, CDCl3 1H, H-7
0), 4.70 (m, 1H, H-
8), 6.96 (d, J=6.4Hz, 1H, NH-9), 7.11 (d, J=9.0Hz,
1H, H-6), 7.36 (dd, J=9.0 and 2.1Hz, 1H, H-5), 7.89 (d,
J=2.1Hz, 1H, H-3), 10.5 (br s, 1H, OH); 13C NMR
(CDCl3, 125MHz) d 27.86 (C-b), 35.87 (C-7), 53.70 (C-
8), 84.40 (C-a), 115.35 (CF3), 120.25 (C-6), 125.24 (C-3),
127.38 (C-4), 133.17 (C-2), 138.55 (C-5), 154.26 (C-1),
156.50 (COCF3), 168.51 (C-10); MS(EI) m/e 378; Anal.
calcd for C15H17F3N2O6 (378.3): C, 46.62; H, 4.52; N,
7.4. Found: C, 47.7; H, 4.42; N, 7.1.
N - (Trifluoroacetyl) -O - methyl - ortho - nitro - L - tyrosine
terbutylester (3a). The reaction was conducted under
argon atmosphere. To a solution of 2 (727mg,
1.92mmol) in acetonitrile (150mL) were added iodo-
methane (0.140mL, 312mg, 2.248mmol, 1.17 equiv),
potassium carbonate (268mg, 1.94mmol) and [18-c-
6]crown-ether (54mg, 0.203mmol, 0.105 equiv). The
mixture was refluxed, under stirring, during 48 h (TLC
control). CH3CNwas removed under vacuum; the residue
was dissolved in CH2Cl2 (100mL) and washed with water
(320mL). Drying over MgSO4, concentration and
flash chromatography on silica gel (hexane:isopropanol,
9:1) gave 698mg of 3a contaminated with the methyl-
ation product of the trifluoroacetamide fraction (1H
NMR: 2.91 d (s, 3H); 13C NMR: 32.99 ppm; MS
(FAB+) m/e 407). The product was further purified by
preparative MPLC on reverse phase (Novapak 4m;
methanol:water, 3:2; 1mL/min) to furnish 548mg (yield:
72%) of 3a: Rf (hexane:iPrOH, 9:1)=0.4; IR (KBr) n
3345, 2980, 1726, 1625, 1531 cmÿ1; 1H NMR (CDCl3,
500MHz) d 1.46 (s, 9H, H-b), 3.13 (dd, J=5.2 and
14.2Hz, 1H, H-7), 3.23 (dd, J=6.4 and 14.2Hz, 1H, H-
70), 3.94 (s, 3H, H-a), 4.68 (m, 1H, H-8), 6.98 (d,
J=7.3Hz, 1H, NH-9), 7.03 (d, J=8.6Hz, 1H, H-6),
7.31 (dd, J=2.1 and 8.6Hz, 1H, H-5), 7.64 (d,
J=2.1Hz, 1H, H-3); 13C NMR (CDCl3, 125MHz) d
27.78 (C-b), 35.76 (C-7), 53.77 (C-8), 56.45 (C-a), 84.25
(C-a), 113.74 (C-6), 115.42 (CF3), 126.34 (C-3), 127.41
(C-4), 135.96 (C-5), 139.23 (C-2), 152.24 (C-1), 156.48
(COCF3), 168.51 (C-10); MS(FAB
-) m/e 391 (M-1), 335
(M-tBu); Anal. calcd for C16H19F3N2O6 (392.23): C, 48.98;
H, 4.88; N, 7.14. Found: C, 48.91; H, 4.94; N, 6.77.
N-(Trifluoroacetyl)-O-[N-(terbutoxycarbonyl)-3-amino-
propyl]-ortho-nitro-L-tyrosine terbutylester (3b). N-(Ter-
butoxycarbonyl)-3-bromopropylamine was obtained
by protection of 3-bromopropylamine as usual: a solu-
tion of 3-bromopropylamine hydrobromide (4.97 g,
22.28mmol) in terbutanol–water (100–130mL) was
treated with diterbutyl dicarbonate (5.27mL, 5.01 g,
22.28mmol, 1 equiv) and sodium hydroxide (1.87 g,
46.89mmol, 2.1 equiv) during 16 h at 20 C. The mix-
ture was extracted with pentane; the organic phase was
washed with 10% NaHCO3 and water, dried over
MgSO4 and concentrated under vacuum to give 4.51 g
(yield: 85%) of N-Boc-3-bromopropylamine: mp 33–
34 C; 1H NMR (CDCl3, 500MHz) d 1.38 (s, 9H), 1.99
(m, 2H), 3.21 (m, 2H), 3.38 (t, 2H), 4.83 (m, NH); 13C
NMR (CDCl3, 125MHz) d 28.15, 30.61, 32.52, 38.75,
79.09, 155.78; MS(EI) m/e 239, 237.
To a solution of 2 (371mg, 0.979mmol) in CH3CN
(35mL), under argon atmosphere, were added N-Boc-3-
bromopropylamine (233mg, 0.976mmol, 1 equiv),
potassium carbonate (149mg, 1.077mmol) and [18-c-6]
crown-ether (0.269mg). The mixture was refluxed,
under stirring, during 22 h (TLC control), and then
worked up as described for 3a. Flash chromatography
on silica gel (hexane:ethyl acetate, 4:1) furnished 343mg
of 3b (yield: 78%): Rf=0.1; mp 104.7–106.2
C; IR
(CDCl3) n 3423 (NH), 1719 (br, CO), 1534, 1262,
1169 cmÿ1; 1H NMR (CDCl3, 500MHz) d 1.43 (s, 9H,
H-g), 1.48 (s, 9H, H-b), 2.05 (m, 2H, H-b), 3.14 (dd,
J=5.2 and 14.2Hz, 1H, H-7), 3.25 (dd, J=5.9 and
14.2Hz, 1H, H-70), 3.36 (m, 2H, H-c), 4.16 (t, J=7.3Hz,
2H, H-a), 4.69 (m, 1H, H-8), 5.06 (br s, NH-d), 6.94 (d,
J=7.3Hz, NH-9), 7.03 (d, J=8.6Hz, 1H, H-6), 7.30
(dd, J=2.1 and 8.6Hz, 1H, H-5), 7.67 (d, J=2.1Hz,
1H, H-3); 13C NMR (CDCl3, 125MHz) d 27.85 (C-g),
28.25 (C-b), 29.00 (C-b), 35.66 (C-7), 37.90 (C-c), 53.71
(C-8), 67.87 (C-a), 79.06 (C-f), 84.40 (C-a), 114.50 (C-6),
115.40 (CF3), 126.50 (C-3), 127.40 (C-4), 135.16 (C-5),
139.06 (C-2), 151.57 (C-1), 156.05 (c-e), 156.40
(COCF3), 168.50 (C-10); Anal. calcd for C23H32F3N3O8
(535.51): C, 51.58; H, 6.02; N, 7.84. Found: C, 51.60; H,
6.02; N, 7.78.
N - (Trifluoroacetyl) -O -methyl -ortho - amino -L - tyrosine
terbutylester (4a). A solution of 3a (690mg, 1.759mmol)
in methanol (12mL) containing platinium IV oxide
(40mg, 0.177mmol, 1 equiv) was placed in a Parr flask
and shaked under hydrogen atmosphere (p=40 psi)
during 18 h at room temperature. After filtration and
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evaporation of the methanol, the residue was dissolved
in ethyl acetate, dried over MgSO4 and concentrated
under vacuum to give 558mg of crude aniline 4a (yield:
88%): Rf (hexane:ethyl acetate, 7:3)=0.3; IR (CHCl3) n
3368, 3314, 2981, 2927, 1717, 1615, 1501, 1432,
1362 cmÿ1; 1H NMR (CDCl3, 500MHz) d 1.46 (s, 9H,
H-b), 3.04 (m, 2H, H-7), 3.83 (s, 3H, H-a), 4.66 (dt,
J=6.1, 6.1 and 7.7Hz, 1H, H-8), 6.45 (m, 2H, H-3 +
H-5), 6.68 (d, J=8.6Hz, 1H, H-6), 6.76 (d, J=7.7Hz,
NH-9); 13C NMR (CDCl3, 125MHz) d 27.86 (C-b),
36.47 (C-7), 53.83 (C-8), 55.40 (C-a), 83.22 (C-a), 110.28
(C-6), 115.52 (CF3), 115.66 (C-3), 119.05 (C-5), 127.20
(C-4), 136.19 (C-2), 146.57 (C-1), 156.40 (COCF3),
168.98 (C-10); MS (FAB+) m/e 363 (M+1), 262, 307,
289.
N-(Trifluoroacetyl)-O-[N-(terbutoxycarbonyl)-3-amino-
propyl]-ortho-amino-L-tyrosine terbutylester (4b). A
solution of 3b (162mg, 0.303mmol) in methanol
(10mL) containing PtO2 (4.4mg, 0.019mmol, 0.06
equiv) was hydrogenated (Parr apparatus, p=50 psi)
during 5 h at 20 C. After filtration and concentration,
the residue was dissolved in chloroform and dried over
MgSO4. Evaporation under vacuum furnished 125mg
of crude aniline 4b (yield: 82%): 1H NMR (CDCl3,
500MHz) d 1.43 (s, 9H, H-g), 1.46 (s, 9H, H-b), 1.99 (m,
2H, H-b), 3.03 (m, 2H, H-7), 3.34 (m, 2H, H-c), 4.02 (t,
J=7.3Hz, 2H, H-a), 4.66 (m, 1H, H-8), 4.73 (br s, NH-
d), 6.40 (m, 2H, H-3 + H-5), 6.70 (d, J=8.6Hz, 1H, H-
6), 6.77 (br s, NH-9); 13C NMR (CDCl3, 125MHz) d
27.88 (C-b), 28.28 (C-g), 29.65 (C-b), 36.46 (C-7), 37.83
(C-c), 53.81 (C-8), 65.96 (C-a), 78.80 (C-f), 83.25 (C-a),
111.48 (C-6), 115.40 (CF3), 115.80 (C-3), 119.05 (C-5),
127.50 (C-4), 136.40 (C-2), 145.64 (C-1), 155.88 (C-e),
156.40 (COCF3), 168.97 (C-10).
N-(Trifluoroacetyl)-O-methyl-ortho-[6-(N,N0-diterbutoxy-
carbonyl)guanidino-caproyl]-amino-L-tyrosine terbutylester
(10a). To a solution of 4a (514mg, 1.419mmol) in
CH2Cl2 (10mL) were added, successively, the acid
chloride 20b (612mg, 1.561mmol, 1.1 equiv) and pyr-
idine (0.130mL, 127mg, 1.607mmol, 1.13 equiv) in
CH2Cl2 (10mL). The mixture was stirred during 20 h at
room temperature. Washing with 1.5N HCl (220mL),
10% NaHCO3 (220mL), and water (220mL), drying
over MgSO4 and concentration gave crude 10a which
was purified by column-chromatography on silica gel
(hexane:ether, 1:1) to furnish 355mg of 10a (yield:
35%): mp 53.7–54.6 C; IR (KBr) n 3338, 2980, 2935,
1724, 1641, 1619, 1535, 1483, 1420, 1369, 1334,
1228 cmÿ1; 1H NMR (CDCl3, 500MHz) d 1.44 (m, 2H,
H-15), 1.46 (s, 9H, H-b), 1.48 (s, 9H, H-23), 1.49 (s, 9H,
H-26), 1.62 (m, 2H, H-16), 1.74 (m, 2H, H-14), 2.38 (t,
J=7.3Hz, 2H, H-13), 3.05 (dd, J=6.0 and 14.2Hz, 1H,
H-7), 3.16 (dd, J=6.0 and 14.2Hz, 1H, H-70), 3.41 (m,
2H, H-17), 3.85 (s, 3H, H-a), 4.67 (m, 1H, H-8), 6.77 (m,
2H, H-5 + H-6), 6.83 (s, 1H, NH-9), 7.71 (s, 1H, NH-
11), 8.25 (s, 1H, H-3), 8.31 (m, 1H, NH-18), 11.50 (s,
1H, NH-20); 13C NMR (CDCl3, 125MHz) d 25.15 (C-
14), 26.29 (C-15), 27.81 (c-b), 27.95 (C-26), 28.18 (C-23),
28.66 (C-16), 36.71 (C-7), 37.63 (C-13), 40.61 (C-17),
53.87 (C-8), 55.61 (C-a), 79.06 (C-22), 82.93 (C-25),
83.49 (C-a), 109.75 (C-6), 115.52 (CF3), 120.52 (C-3),
124.00 (C-5), 127.44 (C-4), 127.73 (C-2), 146.80 (C-1),
153.21 (C-24), 156.01 (C-21), 156.40 (COCF3), 163.51
(C-19), 168.94 (C-10), 170.61 (C-12); Anal. calcd for
C33H50F3N5O9 (717.78): C, 55.22; H, 7.02; N, 9.75.
Found: C, 56.23; H, 7.31; N, 9.13.
N -(Trifluoroacetyl)-O - [N-terbutoxycarbonyl)-3-amino-
propyl] -ortho - [6 - (N,N0 - diterbutoxycarbonyl)guanidino-
caproyl]-amino-L-tyrosine terbutylester (10b). To a
solution of 4a (874mg, 1.728mmol) and pyridine
(411mg, 5.192mmol, 3 equiv) in CH2Cl2 (10mL), was
added the acid chloride 20b (742mg, 1.893mmol, 1.09
equiv) in CH2Cl2 (10mL). The mixture was stirred for
15 h at room temperature, under molecular sieves (4 A˚).
Washing with 1.5N HCl (220mL), 10% NaHCO3
(220mL), and brine (220mL), drying over MgSO4
and concentration gave crude 10b which was flash-
chromatographed (silica gel, hexane:isopropanol, 9:1) to
furnish 750mg of 10b (yield: 51%): Rf=0.3;
1H NMR
(CDCl3, 500MHz) d 1.41 (s, 9H, H-g), 1.44 (m, 2H, H-
15), 1.47 (s, 9H, H-b), 1.49 (s, 9H, H-23), 1.50 (s, 9H, H-
26), 1.62 (m, 2H, H-16), 1.76 (m, 2H, H-14), 1.97 (m,
2H, H-b), 2.46 (t, J=7.3Hz, 2H, H-13), 3.05 (dd, J=6.0
and 14.2Hz, 1H, H-7), 3.16 (dd, J=5.2 and 14.2Hz,
1H, H-70), 3.35 (m, 2H, H-c), 3.41 (m, 2H, H-17), 4.07
(t, J=7.0Hz, 2H, H-a), 4.68 (m, 1H, H-8), 4.74 (m, 1H,
NH-d), 6.75 (dd, J=2.1 and 9.0Hz, 1H, H-5), 6.79 (d,
J=9.0Hz, 1H, H-6), 6.87 (d, J=7.8Hz, 1H, NH-9),
8.17 (s, 1H, NH-11), 8.22 (d, J=2.1Hz, 1H, H-3),
8.31(m, 1H, NH-18), 11.50 (s, 1H, NH-20); 13C NMR
(CDCl3, 125MHz) d 25.24 (C-14), 26.36 (C-15), 27.80
(C-b), 27.93 (C-26), 28.20 (C-23 and C-g), 28.75 (C-16),
29.58 (C-b), 36.68 (C-7), 36.86 (C-c), 37.37 (C-13), 40.65
(C-17), 53.87 (C-8), 65.23 (C-a), 79.05 (C-22), 79.28 (C-
f), 82.89 (C-25), 83.45 (C-a), 111.18 (C-6), 115.52 (CF3),
121.20 (C-3), 123.99 (C-5), 127.58 (C-4), 128.31 (C-2),
146.10 (C-1), 153.18 (C-24), 155.98 (C-21 and C-e),
156.30 (COCF3), 163.50 (C-19), 168.92 (C-10), 171.11
(C-12); Anal. calcd for C40H63F3N6O11 (860.96): C,
55.8; H, 7.37; N, 9.76. Found: C, 55.64; H, 7.06; N,
9.06.
N-(Trifluoroacetyl)-O-methyl-ortho-[6-(benzyloxycarbonyl)-
amino-caproyl]-amino-L-tyrosine terbutylester (6a). N-
(Benzyloxycarbonyl)-6-aminocaproyl chloride was pre-
pared from N-(benzyloxycarbonyl)-6-aminocaproic acid
(644mg, 2.43mmol) in CH2Cl2 (25mL) treated with
thionyl chloride (0.9mL, 1.47 g, 12.3mmol, 5 equiv) for
2 h at reflux; concentration under high vacuum gave the
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crude acid chloride (625mg, 91% yield). To a solution
of 4a (464mg, 1.28mmol) in CH2Cl2 (4mL) were added
successively N-(benzyloxycarbonyl)-6-aminocaproyl
chloride (400mg, 1.41mmol, 1.1 equiv) and pyridine
(303mg, 3.83mmol, 4 equiv) in CH2Cl2 (4mL). The
mixture was stirred for 20 h at 20 C, then washed twice
with 1.5N HCl, 10% NaHCO3 and water. Drying
(MgSO4), concentration and flash-chromatography
(CHCl3) gave 196mg of 6a (yield: 25%): Rf=0.2; IR
(CHCl3) n 3315, 2933, 1718, 1654, 1596, 1560, 1535,
1483 cmÿ1; 1H NMR (CDCl3, 500MHz) d 1.39 (m, 2H,
H-15), 1.46 (s, 9H, H-b), 1.54 (m, 2H, H-16), 1.73 (m,
2H, H-14), 2.36 (t, J=7.3Hz, 2H, H-13), 3.04 (dd,
J=6.1 and 14.0Hz, 1H, H-7), 3.16 (dd, J=5.8 and
14.0Hz, 1H, H-70), 3.19 (m, 2H, H-17), 3.85 (s, 3H, H-
a), 4.68 (dt, J=6.1, 5.8 and 7.3Hz, 1H, H-8), 4.84 (m,
1H, NH-18), 5.08 (s, 2H, H-21), 6.78 (m, 2H, H-5 + H-
6), 6.89 (d, J=7.3Hz, 1H, NH-9), 7.27–7.37 (m, 5H,
Ph), 7.71 (s, 1H, NH-11), 8.25 (s, 1H, H-3); 13C NMR
(CDCl3, 125MHz) d 25.02 (C-14), 26.11 (C-15), 27.78
(c-b), 29.58 (C-16), 36.70 (C-7), 36.61 (C-13), 40.72 (C-
17), 53.87 (C-8), 55.58 (C-a), 66.42 (C-21), 83.43 (C-a),
109.74 (C-6), 115.42 (CF3), 120.48 (C-3), 124.02 (C-5),
127.46 (C-4), 127.66 (C-2), 127.90 (C-24 + C-25),
128.35 (C-23), 136.51 (C-22), 146.71 (C-1), 156.26
(C-19), 156.4 (COCF3), 168.95 (C-10), 170.61 (C-12);
MS (FAB+) m/e 510 (M+1-Boc), 446, 136, 95, 91, 83,
69.
N-(Trifluoroacetyl)-O-methyl-ortho-[N-(benzyloxycarbon-
yl)-isonipecotyl]-amino-L-tyrosine terbutylester (7a). N-
(Benzyloxycarbonyl)-isonipecotyl chloride was prepared
from N-(benzyloxycarbonyl)-isonipecotic acid (331mg,
1.257mmol) in CH2Cl2 (25mL) treated with SOCl2
(0.49mL, 800mg, 6.72mmol, 5.3 equiv) for 1 h 30min
at reflux; concentration under high vacuum gave the
crude acid chloride (343mg, 97%). To a solution of 4a
(404mg, 1.115mmol) in CH2Cl2 (10mL) were added
successively N-(benzyloxycarbonyl)-isonipecotyl chlor-
ide (343mg, 1.218mmol, 1.09 equiv) in CH2Cl2 (10mL),
and pyridine (0.1mL, 98mg, 1.236mmol, 1.11 equiv).
The mixture was stirred for 16 h at 20 C (TLC control),
then washed with 1N HCl (310mL), 10% NaHCO3
(310mL), and brine (310mL). Drying (MgSO4),
concentration and flash-chromatography (silica gel,
hexane-isopropanol, 10:1) gave 380mg of 7a (yield:
56%): Rf=0.1; mp 62.3–63.5
C; IR (KBr) n 3422,
3309, 3083, 2944, 1717, 1696, 1675, 1597, 1536,
1369 cmÿ1; 1H NMR (CDCl3, 500MHz) d 1.46 (s, 9H,
H-b), 1.74 (m, 2H, H-14), 1.90 (m, 2H, H-140), 2.43 (m,
1H, H-13), 2.88 (m, 2H, H-15), 3.03 (dd, J=6.1 and
14.0Hz, 1H, H-7), 3.16 (dd, J=5.2 and 14.0Hz, 1H, H-
70), 3.85 (s, 3H, H-a), 4.23 (m, 2H, H-150), 4.67 (m, 1H,
H-8), 5.13 (s, 2H, H-18), 6.78 (m, 2H, H-5 + H-6), 7.03
(d, J=7.6Hz, 1H, NH-9), 7.27–7.37 (m, 5H, Ph), 7.81
(s, 1H, NH-11), 8.25 (d, J=2.1Hz, 1H, H-3); 13C NMR
(CDCl3, 125MHz) d 27.66 (C-b), 28.22 (C-14), 28.36 (C-
140), 36.56 (C-7), 43.08 (C-15), 44.01 (C-13), 53.87 (C-8),
55.51 (C-a), 66.92 (C-18), 83.32 (C-a), 109.67 (C-6),
115.44 (CF3), 120.50 (C-3), 124.16 (C-5), 127.33 (C-2),
127.48 (C-4), 127.64 (C-21), 127.77 (C-22), 128.25 (C-
20), 136.51 (C-19), 146.83 (C-1), 154.96 (C-17), 156.26
(COCF3), 168.87 (C-10), 171.91 (C-12); HRMS
(FAB+): calcd for C30H36F3N3O7: 607.2505. Found:
607.2528.
N-(Trifluoroacetyl)-O-methyl-ortho-[N-(benzyloxycarbon-
yl)-nipecotyl]-amino-L-tyrosine terbutylester (8a). N-
(Benzyloxycarbonyl)-nipecotyl chloride (335mg, 95%
yield) was prepared, as above, from N-(benzyloxy-
carbonyl)-nipecotic acid (330mg, 1.25mmol) and SOCl2
(750mg, 6.3mmol, 5 equiv). To a solution of 4a
(384mg, 1.06mmol) and pyridine (0.1mL, 98mg,
1.236mmol, 1.17 equiv) in CH2Cl2 (10mL), was added
N-(benzyloxycarbonyl)-nipecotyl chloride (335mg,
1.19mmol, 1.12 equiv) in CH2Cl2 (10mL). The mixture
was stirred for 17 h at 20 C (TLC control), then
worked-up as above. Flash-chromatography (silica gel,
CH2Cl2:EtOAc, 9:1) gave 318mg of 8a (yield: 49%): mp
50–51 C; IR (film) n 3417, 2944, 2865, 1718, 1685,
1597, 1536, 1482, 1433, 1370, 1259, 1154 cmÿ1; 1H
NMR (CDCl3, 500MHz) d 1.46 (s, 9H, H-b), 1.52 (m,
1H, H-17), 1.76 (m, 1H, H-18), 1.80 (m, 1H, H-170), 2.02
(m, 1H, H-180), 2.48 (m, 1H, H-13), 2.90 (m, 1H, H-16),
3.04 (dd, J=6.1 and 14.0Hz, 1H, H-7), 3.05 (m, 0.5 H,
H-14), 3.15 (m, 0.5 H, H-14), 3.16 (dd, J=5.2 and
14.0Hz, 1H, H-70), 3.84 (s, 3H, H-a), 4.10 (m, 1H, H-
160), 4.21 (m, 0.5 H, H-140), 4.31 (m, 0.5 H, H-140), 4.67
(m, 1H, H-8), 5.14 (s, 2H, H-20), 6.78 (m, 2H, H-5 + H-
6), 6.81 (d, J=7.9Hz, 1H, NH-9), 7.28–7.38 (m, 5H,
Ph), 7.81 (s, 1H, NH-11), 8.23 (m, 1H, H-3); 13C NMR
(CDCl3, 125MHz) d 24.18 (C-17), 27.65 (C-18), 27.82
(C-b), 36.78 (C-7), 44.14 (C-16), 44.52 (C-13), 46.36 (C-
14), 53.90 (C-8), 55.63 (C-a), 67.12 (C-20), 83.56 (C-a),
109.81 (C-6), 115.44 (CF3), 120.68 (C-3), 124.36 (C-5),
127.40 (C-4), 127.46 (C-2), 127.80 (C-23), 127.94 (C-24),
128.41 (C-22), 136.59 (C-21), 146.97 (C-1), 155.19 (C-
19), 156.40 (COCF3), 168.95 (C-10), 170.85 (C-12); MS
(FAB+) m/e 608.5; Anal. calcd for C30H36F3N3O7
(607.62): C, 59.3; H, 5.97; N, 6.91. Found: C, 58.72; H,
5.98; N, 6.64.
N-(Trifluoroacetyl)-O-methyl-ortho-(6-guanidino-caproyl)-
amino-(L)-tyrosine (16a). The Boc-protected precursor
10a (76.5mg, 0.106mmol) was dissolved in trifluoro-
acetic acid (1.7mL) and left for 2.5 h at 20 C. After
evaporation under vacuum, the residue was dissolved in
water and washed with chloroform. The aqueous phase
was freeze-dried to give 58mg of 16a (yield: 86%): mp
95.5–96.5 C; IR (KBr) n 3416, 1664, 1542, 1206,
1138 cmÿ1; 1H NMR (D2O, 500MHz) d 1.44 (m, 2H, H-
15), 1.64 (m, 2H, H-16), 1.73 (m, 2H, H-14), 2.47 (t,
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J=7.3Hz, 2H, H-13), 2.98 (dd, J=9.5 and 14.0Hz, 1H,
H-7), 3.20 (t, J=7.3Hz, 2H, H-17), 3.30 (dd, J=5.2 and
14.0Hz, 1H, H-70), 3.85 (s, 3H, H-a), 4.68 (dd, J=9.5
and 5.2Hz, 1H, H-8), 7.06 (d, J=8.6Hz, 1H, H-6),
7.15 (dd, J=2.1 and 8.6Hz, 1H, H-5), 7.44 (d,
J=2.1Hz, 1H, H-3); 13C NMR (D2O, 125MHz) d 27.45
(C-14), 27.80 (C-15), 30.14 (C-16), 38.44 (C-13),
38.54 (C-7), 43.58 (C-17), 57.79 (C-8), 58.55 (C-a),
114,82 (C-6), 118.37 (CF3), 127,71 (C-4), 128.04 (C-3),
130.41 (C-5), 131.58 (C-2), 153.40 (C-1), 159.33 (C-19),
160.85 (COCF3), 176.83 (C-12), 178.51 (C-10); HRMS
(FAB+): calcd for C21H27F6N5O7: 462.1964. Found:
462.1971.
N-(Trifluoroacetyl)-O-(3-aminopropyl)-ortho-(6-guanidino-
caproyl)-amino-L-tyrosine (16b). The Boc-protected
precursor 10b (750mg, 0.871mmol) was dissolved in
CF3CO2H (13.5mL) and left for 2 h at 20
C. Work up
as above gave 616mg of 16b (yield: 97%): [a]d20 +2.5
(c 1, H2O);
1H NMR (D2O, 500MHz) d 1.44 (m, 2H, H-
15), 1.63 (m, 2H, H-16), 1.71 (m, 2H, H-14), 2.13 (m,
2H, H-b), 2.45 (t, J=7.3Hz, 2H, H-13), 2.96 (m, 1H, H-
7), 3.16 (m, 2H, H-c), 3.20 (t, J=7.3Hz, 2H, H-17), 3.28
(m, 1H, H-70), 4.16 (t, J=7.3Hz, 2H, H-a), 4.68 (m, 1H,
H-8), 7.04 (d, J=8.6Hz, 1H, H-6), 7.16 (m, 1H, H-5),
7.27 (m, 1H, H-3); 13C NMR (D2O, 125MHz) d 27.45
(C-14), 27.77 (C-15), 28.92 (C-b), 30.06 (C-16), 38.28 (C-
7 + C-13), 39.65 (C-c), 43.45 (C-17), 57.62 (C-8), 68.46
(C-a), 115.89 (C-6), 118.37 (CF3), 127.50 (C-4), 129.22
(C-3), 130.96 (C-5), 132.01 (C-2), 153.00 (C-1), 159.24
(C-19), 160.84 (COCF3), 176.61 (C-12), 178.50 (C-10);
HRMS (FAB+): calcd for C21H32F3N6O5: 505.2386.
Found: 505.2385.
N-(Trifluoroacetyl)-O-methyl-ortho-(6-amino-caproyl)-
amino-L-tyrosine (12a). A solution of 6a (55mg,
0.09mmol) in EtOAc (5mL)) was placed in a Parr flask
and hydrogenated (pH2=40psi) in the presence of
Palladium (10% on C, 2mg, 0.21 equiv). The mixture
was vigorously shaked during 72 h (fresh catalyst was
added three times). After filtration and concentration,
the residue was dissolved in CHCl3, dried over MgSO4
and concentrated under vacuum. The residue was dis-
solved in CF3CO2H (2mL) and left for 2.5 h at 20
C.
After evaporation, the residue was dissolved in water
and extracted with CHCl3. The aqueous phase was
freeze-dried to give 40mg of 12a (yield: 100%): IR
(CD3OD) n 3419, 2947, 2361, 1683, 1541, 1490, 1207,
1143, 1029 cmÿ1; 1H NMR (CD3OD, 500MHz) d 1.47
(m, 2H, H-15), 1.71 (m, 4H, H-14 + H-16), 2.46 (t,
J=7.3Hz, 2H, H-13), 2.93 (t, J=7.3Hz, 2H, H-17),
2.96 (dd, J=9.5 and 14.2Hz, 1H, H-7), 3.23 (dd, J=5.2
and 14.2Hz, 1H, H-70), 3.84 (s, 3H, H-a), 4.61 (m, 1H,
H-8), 6.91 (d, J=8.6Hz, 3H, H-6), 6.96 (dd, J=2.1 and
8.6Hz, 1H, H-5), 7.84 (d, J=2.1Hz, 1H, H-3); 13C
NMR (CD3OD, 125MHz) d 26.16 (C-14), 26.88 (C-15),
28.28 (C-16), 37.23 (C-13), 37.32 (C-7), 40.57 (C-17),
55.93 (C-8), 56.33 (C-a), 111.77 (C-6), 117.34 (CF3),
124.41 (C-3), 126.89 (C-5), 127.99 (C-4), 130.15 (C-2),
150.63 (C-1), 158.71 (COCF3), 173.98 (C-10), 174.37 (C-
12); HRMS (FAB+): calcd for C18H24F3N3O5:
420.1746. Found: 420.1749.
N-(Trifluoroacetyl)-O-methyl-ortho-(isonipecotyl)-amino-
L-tyrosine (13a). A solution of 7a (130mg, 0.214mmol)
in EtOAc:EtOH (1:1, 10mL) was placed in a Parr flask
and hydrogenated (pH2=40 psi) in the presence of Pal-
ladium (10% on C; 23mg, 0.021mmol), during 18 h
under vigorous shaking. After filtration and concentra-
tion under vacuum, the residue (93mg) was dissolved in
CF3CO2H (3mL) and left for 2.5 h at 20
C. Workup as
above gave 100mg (Yield: 100%) of 13a: 1H NMR
(D2O, 500MHz) d 1.94 (m, 2H, H-14), 2.16 (m, 2H, H-
140), 2.85 (tt, J=3.4 and 11.9Hz, 1H, H-13), 2.97 (dd,
J=9.5 and 14.Hz, 1H, H-7), 3.11 (m, 2H, H-15), 3.29
(dd, J=5.2 and 14Hz, 1H, H-70), 3.53 (m, 2H, H-150),
3.83 (s, 3H, H-a), 4.75 (m, 1H, H-8), 7.03 (d, J=8.8Hz,
1H, H-6), 7.13 (dd, J=2.1 and 8.8Hz, 1H, H-5), 7.44 (d,
J=2.1Hz, 1H, H-3); 13C NMR (D2O, 125MHz) ppm
27.55 (C-14), 27.63 (C-140), 38.20 (C-7), 42.64 (C-13),
45.61 (C-15), 57.00 (C-8), 58.52 (C-a), 114.74 (C-6),
118.11 (CF3), 127.53 (C-4), 127.76 (C-3), 130.39 (C-5),
131.17 (C-2), 153.30 (C-1), 160.96 (COCF3), 175.84 (C-
12), 177.66 (C-10); HRMS: calcd for C18H22F3N3O5:
418.1590. Found: 418.1603.
N-(Trifluoroacetyl)-O-methyl-ortho-(nipecotyl))-amino-L-
tyrosine (14a). A solution of 8a (160mg, 0.263mmol) in
EtOAc:-EtOH (1:1, 10mL) was placed in a Parr flask
and hydrogenated (pH2=40 psi) in the presence of Pal-
ladium (10% on C; 28mg, 0.026mmol), under vigorous
shaking, during 18 h. After filtration and concentration,
the residue (111mg) was dissolved in CF3CO2H
(3.5mL) and left for 2.5 h at 20 C. Work up as above
gave 120mg (yield: 100%) of 14a: 1H NMR (D2O,
500MHz) d 1.85 (m, 2H, H-17 + H-18), 1.99 (m, 1H,
H-170), 2.15 (m, 1H, H-180), 2.97 (m, 1H, H-7), 3.03 (m,
1H, H-13), 3.11 (m, 1H, H-16), 3.29 (m, 2H, H-160 +
H-14), 3.29 (m, 1H, H-70), 3.45 (m, 1H, H-140), 3.83 (s,
3H, H-a), 4.75 (m, 1H, H-8), 7.03 (d, J=8.6Hz, 1H, H-
6), 7.13 (dd, J=2.1 and 8.6Hz, 1H, H-5), 7.45 (d,
J=2.1Hz, 1H, H-3); 13C NMR (D2O, 125MHz) d 23.07
(C-17), 28.25–28.30 (C-18), 38.07–38.13 (C-7), 41.76 (C-
13), 46.41 (C-16), 47.22 (C-14), 56.91 (C-8), 58.52 (C-a),
114.76 (C-6), 118.13 (CF3), 127.32 (C-4), 127.78–127.86
(C-3), 130.50–130.56 (C-5), 131.14 (C-2), 153.30–153.38
(C-1), 160.96 (COCF3), 175.78 (C-12), 176.11 (C-10);
HRMS: calcd for C18H22F3N3O5: 418.1590. Found:
418.1587.
O-Methyl-ortho-nitro-L-tyrosine terbutylester (22). To a
solution of 3a (2.27 g, 5.785mmol) in MeOH:H2O (1:1,
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100mL), was added K2CO3 (4.207 g, 30.14mmol). The
mixture was stirred during 17 h at 20 C, then con-
centrated under vacuum. Toluene was added and dis-
tilled. The residue was dissolved in CH2Cl2 and washed
with water (3). The organic phase was dried (MgSO4),
and concentrated under vacuum to give the crude amine
22 (1.504 g, 88% yield): Rf (SiO2; CH2Cl2:EtOAc,
9:1)=0.1; IR (CHCl3) n 3383, 2977, 2934, 1727, 1623,
1531, 1506, 1457, 1358, 1289, 1260, 1154, 1090,
1019 cmÿ1; 1H NMR (CDCl3, 500MHz) d 1.42 (s, 9H,
H-b), 2.83 (dd, J=7.3 and 14.2Hz, 1H, H-7), 2.98 (dd,
J=5.5 and 14.2Hz, 1H, H-70), 3.56 (m, 1H, H-8), 3.93
(s, 3H, H-a), 7.01 (d, J=8.6Hz, 1H, H-6), 7.41 (dd,
J=2.1 and 8.6Hz, 1H, H-5), 7.72 (d, J=2.1Hz, 1H, H-3);
13C NMR (CDCl3, 125MHz) d 27.88 (C-b), 39.48 (C-7),
55.91 (C-8), 56.44 (C-a), 81.49 (C-a), 113.38 (C-6), 126.21
(C-3), 130.07 (C-4), 135.12 (C-5), 139.25 (C-2), 151.69
(C-1), 173.82 (C-10); MS (FAB+) m/e 297, 241, 57.
N-(meta-Trifluoromethyl-benzenesulfonyl)-O-methyl-ortho-
nitro-L-tyrosine terbutyl ester (23). To a solution of 22
(1.454 g, 4.91mmol) in CH2Cl2 (63mL), were added
successively Et3N (0.75mL, 0.546mg, 5.397mmol, 1.1
equiv) and meta-trifluoromethyl-benzenesulfonyl chlor-
ide (0.865mL, 1.32 g, 5.397mmol, 1.1 equiv). The mix-
ture was stirred at 20 C during 20 h, then washed with
1N HCl (210mL) and water (210mL). After drying
(MgSO4), concentration and flash-chromatography
(silica gel, CHCl3), the sulfonamide 23 was recovered
(1.26 g, 51% yield): IR (CDCl3) n 3650, 3273, 3076,
2982, 2937, 2846, 1733, 1624, 1575, 1534, 1160 cmÿ1; 1H
NMR (CDCl3, 500MHz) d 1.22 (s, 9H, H-b), 2.93 (dd,
J=7.3 and 14.2Hz, 1H, H-7), 3.04 (dd, J=5.9 and
14.2Hz, 1H, H-7), 3.87 (s, 3H, H-a), 4.05 (m, 1H, H-8),
5.75 (br s, 1H, NH-9), 6.95 (d, J=8.6Hz, 1H, H-6), 7.36
(dd, J=2.1 and 8.6Hz, 1H, H-5), 7.58 (d, J=2.1Hz,
1H, H-3), 7.58 (t, J=8.0Hz, 1H, H-y), 7.75 (d,
J=8.0Hz, 1H, H-x), 7.93 (d, J=8.0Hz, 1H, H-z), 8.00
(s, 1H, H-v); 13C NMR (CDCl3, 125MHz) d 27.38 (C-
b), 37.68 (C-7), 56.24 (C-a), 56.85 (C-8), 83.43 (C-a),
113.46 (C-6), 122.91 (CF3), 123.80 (C-v), 126.24 (C-3),
127.48 (C-4), 129.15 (C-x), 129.75 (C-y), 130.22 (C-z),
131.34 (C-w), 135.41 (C-5), 138.85 (C-u), 140.84 (C-2),
151.94 (C-1), 169.14 (C-10); MS (FAB-) m/e 503 (M–1),
209; Anal. calcd for C21H23F3N2O7S (504.47): C, 49.99;
H, 4.59; N, 5.55; S, 6.35. Found: C, 49.79; H, 4.50; N,
5.28; S, 6.09.
N-(meta-Trifluoromethyl-benzenesulfonyl)-O-methyl-ortho-
amino-L-tyrosine terbutylester (24). A solution of 23
(1.259 g, 2.495mmol) in methanol (20mL) was placed in
a Parr flask and hydrogenatad (pH2=40 psi) in the pre-
sence of platinium IV oxide (56.7mg, 0.249mmol, 0.1
equiv), under vigorous shaking, during 17 h at 20 C.
After filtration and concentration, the residue was dis-
solved in CH2Cl2 and dried over MgSO4. Concentration
under vacuum gave 1.074 g of crude 23 (Yield: 91%):
mp 40–41 C; IR (CHCl3) n 3275, 2980, 1734, 1617,
1517, 1438, 1327, 1280, 1232, 1161, 1132, 1105 cmÿ1; 1H
NMR (CDCl3, 300MHz) d 1.24 (s, 9H, H-b), 2.90 (m,
2H, H-7), 3.80 (s, 3H, H-a), 4.06 (m, 1H, H-8), 5.44 (d,
1H, NH-9), 6.52 (d, 1H, H-5), 6.63 (d + s, 2H, H-6 +
H-3), 7.58 (t, 1H, H-y), 7.76 (d, 1H, H-x), 7.93 (d, 1H,
H-z), 8.04 (s, 1H, H-v); 13C NMR (CDCl3, 75MHz) d
27.59 (C-b), 38.58 (C-7), 55.44 (C-a), 57.17 (C-8), 82.69
(C-a), 110.37 (C-6), 117.32 (C-3), 120.82 (C-5), 122.9
(CF3), 124.04 (C-v), 127.53 (C-4), 129.0 (C-x), 129.64
(C-y), 130.42 (C-z), 131.4 (C-w), 133.56 (C-2), 141.3 (C-
u), 147.13 (C-1), 169.61 (C-10); MS (FAB+) m/e 475
(M+1), 474, 419, 401, 373.
N-(meta-Trifluoromethyl-benzenesulfonyl)-O-methyl-ortho-
[6-N,N0-(diterbutoxycarbonyl) guanidino-caproyl]-amino-
L-tyrosine terbutylester (26). To a solution of 24
(229mg, 0.483mmol) in CH2Cl2 (5mL) were added the
acid chloride 20b (207mg, 0.528mmol, 1.09 equiv) and
pyridine (0.117mL, 114mg, 1.447mmol, 3 equiv) in
CH2Cl2 (5mL). The mixture was stirred at 20
C for
20 h, then washed twice with 1.5 N HCl, and water.
Drying (MgSO4), concentration and flash chromato-
graphy (silica gel, CH2Cl2:EtOAc, 9:1) gave 92mg
(Yield: 24%) of 26: IR (CDCl3) n 3332, 2978, 2930,
1723, 1641, 1617, 1537, 1481, 1161, 1134 cmÿ1; 1H
NMR (CDCl3, 500MHz) d 1.27 (s, 9H, H-b), 1.44 (m,
2H, H-15), 1.48 (s, 9H, H-23), 1.49 (s, 9H, H-26), 1.62
(m, 2H, H-16), 1.74 (m, 2H, H-14), 2.37 (m, 2H, H-13),
2.86 (dd, J=7.3 and 14.2Hz, 1H, H-7), 3.00 (dd, J=5.2
and 14.2Hz, 1H, H-70), 3.41 (m, 2H, H-17), 3.84 (s, 3H,
H-a), 4.06 (m, 1H, H-8), 5.23 (d, J=9.4Hz, 1H, NH-9),
6.72 (d, J=8.6Hz, 1H, H-6), 6.82 (dd, J=2.1 and
8.6Hz, 1H, H-5), 7.55 (dd, J=8.0Hz, 1H, H-y), 7.67 (s,
1H, NH-11), 7.73 (d, J=8.0Hz, 1H, H-x), 7.94 (d,
J=8.0Hz, 1H, H-z), 7.99 (s, 1H, H-v), 8.14 (d,
J=2.1Hz, 1H, H-3), 8.31 (m, 1H, NH-18), 11.50 (s, 1H,
NH-20); 13C NMR (CDCl3, 125MHz) d 25.09 (C-14),
26.35 (C-15), 27.58 (C-b), 27.96 (C-26), 28.19 (C-23),
28.69 (C-16), 37.61 (C-13), 38.72 (C-7), 40.65 (C-17),
55.54 (C-a), 57.14 (C-8), 79.14 (C-22), 82.96 (C-25 +
C-a), 109.60 (C-6), 120.50 (C-3), 122.91 (CF3), 124.12
(C-v), 124.39 (C-5), 127.48 (C-4), 127.56 (C-2), 128.93
(C-x), 129.53 (C-y), 130.51 (C-z), 131.37 (C-w), 141.20
(C-u), 146.65 (C-1), 153.24 (C-24), 156.00 (C-21), 163.47
(C-19), 169.67 (C-10), 170.58 (C-12); MS (FAB-) m/e
829 (M-1) 828, 711, 209; Anal. calcd for
C38H54F3N5O10S (829.92): C, 54.99; H, 6.55 ; N, 8.43.
Found: C, 55.10; H, 6.20; N, 8.16.
N-(meta-Trifluoromethyl-benzene sulfonyl)-O-methyl-ortho-
[6-(benzyloxycarbonyl) amino-caproyl]-amino-L-tyrosine
terbutylester (25). To a solution of 24 (669mg,
1.409mmol) in CH2Cl2 (5mL), were added N-(benzyl-
oxycarbonyl) aminocaproyl chloride (400mg, 1.409mmol,
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1 equiv) and pyridine (0.33mL, 323mg, 4.08mmol, 2.89
equiv) in CH2Cl2 (5mL). The mixture was stirred for
20 h at 20 C, then worked-up as before to furnish
490mg (yield: 48%) of 25: IR (film) n 3370, 2937, 1715,
1698, 1597, 1536, 1162 cmÿ1; Rf (SiO2; CH2Cl2:EtOAc,
9:1)=0.1; 1H NMR (CDCl3, 500MHz) d 1.25 (s, 9H, H-
b), 1.37 (m, 2H, H-15), 1.52 (m, 2H, H-16), 1.70 (m, 2H,
H-14), 2.34 (t, J=7.3Hz, 2H, H-13), 2.82 (dd, J=7.3
and 14.2Hz, 1H, H-7), 2.97 (dd, J=5.6 and 14.2Hz,
1H, H-70), 3.18 (m, 2H, H-17), 3.80 (s, 3H, H-a), 4.05
(m, 1H, H-8), 4.96 (m, 1H, NH-18), 5.06 (m, 2H, H-21),
5.61 (d, J=9.5Hz, 1H, NH-9), 6.68 (d, J=8.6Hz, 1H,
H-6), 6.80 (m, 1H, H-5), 7.27–7.37 (m, 5H, H-23+H-
24+H-25), 7.51 (dd, J=8.0Hz, 1H, H-y), 7.67 (s, 1H,
NH-11), 7.70 (d, J=8.0Hz, 1H, H-x), 7.90 (d,
J=8.0Hz, 1H, H-z), 7.98 (s, 1H, H-v), 8.14 (d,
J=2.1Hz, 1H, H-3); 13C NMR (CDCl3, 125MHz) d
24.88 (C-14), 26.03 (C-15), 27.45 (C-b), 29.48 (C-16),
37.40 (C-13), 38.53 (C-7), 40.65 (C-17), 55.41 (C-a),
57.21 (C-8), 66.29 (C-21), 82.66 (C-a), 109.53 (C-6),
120.42 (C-3), 123.00 (CF3), 123.89 (C-v), 124.30 (C-5),
127.30 (C-4), 127.58 (C-2), 127.80 (C-24+C-25), 128.25
(C-23), 128.71 (C-x), 129.41 (C-y), 130.35 (C-z), 131.11
(C-w), 136.51 (C-22), 141.23 (C-u), 146.55 (C-1), 156.25
(C-19), 169.68 (C-10), 170.61 (C-12); HRMS: calcd for
C35H42F3N3O8S: 721.2645. Found: 721.2647.
N-(meta-Trifluoromethyl-benzenesulfonyl)-O-methyl-ortho-
(6-guanidino-caproyl)-amino-L-tyrosine (28). A solution
of 26 (75mg, 0.131mmol) in trifluoroacetic acid (2mL)
was left for 2 h at 20 C, then evaporated under
vacuum. The residue was dissolved in water and extrac-
ted with CHCl3. Freeze-drying of the aqueous phase
gave 120mg (yield  100%) of 28 (hydroscopic white
powder): 1H NMR (CD3OD, 500MHz) d 1.46 (m, 2H,
H-15), 1.64 (m, 2H, H-16), 1.74 (m, 2H, H-14), 2.45 (t,
J=7.3Hz, 2H, H-13), 2.73 (dd, J=9.5 and 14.0Hz, 1H,
H-7), 3.00 (dd, J=4.6 and 14.0Hz, 1H, H-70), 3.18 (t,
J=7.3Hz, 2H, H-17), 3.81 (s, 3H, H-a), 4.04 (m, 1H, H-
8), 6.74 (d, J=8.6Hz, 1H, H-6), 6.83 (m, 1H, H-5), 7.55
(dd, J=8.0Hz, 1H, H-y), 7.73 (d, J=2.1Hz, 1H, H-3),
7.79 (d, J=8.0Hz, 1H, H-z), 7.81 (d, J=8.0Hz, 1H, H-
x), 7.91 (s, 1H, H-v); 13C NMR (CD3OD, 125MHz) d
26.27 (C-14), 27.21 (C-15), 29.60 (C-16), 37.49
(C-13), 39.25 (C-7), 42.33 (C-17), 56.18 (C-a), 59.34 (C-
8), 111.53 (C-6), 124.22 (C-3), 124.62 (C-v), 124.90
(CF3), 126.91 (C-5), 127.85 (C-4), 129.69 (C-x), 129.80
(C-2), 131.06 (C-y), 131.46 (C-z), 132.02 (C-w), 143.83
(C-u), 150.22 (C-1), 158.68 (C-19), 174.33 (C-12), 174.58
(C-10); HRMS; calcd for C26H31F6N5O8S: 574.1947.
Found: 574.1950.
N-(meta-Trifluoromethyl-benzenesulfonyl)-O-methyl-ortho-
(6-amino-caproyl)-amino-l-tyrosine (27). A solution of 25
(112mg, 0.154mmol) in EtOH:EtOAc (50:50, 10mL)
was placed in a Parr flask and hydrogenated
(pH2=40psi) in the presence of Palladium catalyst
(10% on C, 4.5mg, 0.042mmol, 0.27 equiv) during 18 h
at 20 C, under vigorous shaking. Filtration and con-
centration under vacuum gave a residue which was dis-
solved in trifluoroacetic acid (6mL) and left for 2.5 h at
20 C. Work up as before furnished 88mg (yield: 90%)
of 27 (hygroscopic solid): [a]d20 ÿ7.5 (c 0.04;
H2O:CH3CN, 20:80); IR (film) n 3423, 2948, 2534, 1674,
1655, 1539, 1204, 1136 cmÿ1; 1H NMR (CD3OD,
500MHz) d 1.47 (m, 2H, H-15), 1.72 (m, 4H, H-14+H-
16), 2.46 (t, J=7.3Hz, 2H, H-13), 2.72 (dd, J=9.5 and
14.0Hz, 1H, H-7), 2.94 (m, 2H, H-17), 3.00 (dd, J=5.2
and 14.0Hz, 1H, H-70), 3.81 (s, 3H, H-a), 4.05 (dd,
J=5.2 and 9.5Hz, 1H, H-8), 6.74 (d, J=8.6Hz, 1H, H-
6), 6.83 (dd, J=2.1 and 8.6Hz, 1H, H-5), 7.55 (dd,
J=8.0Hz, 1H, H-y), 7.74 (d, J=2.1Hz, 1H, H-3), 7.78
(d, J=8.0Hz, 1H, H-x), 7.81 (d, J=8.0Hz, 1H, H-z),
7.91 (s, 1H, H-v); 13C NMR (CD3OD, 125MHz) d
26.16 (C-14), 26.93 (C-15), 28.31 (C-16), 37.32 (C-13),
39.22 (C-7), 40.57 (C-17), 56.19 (C-a), 59.27 (C-8),
111.55 (C-6), 124.16 (C-3), 124.64 (C-v), 124.90 (CF3),
126.85 (C-5), 127.89 (C-4), 129.62 (C-x), 129.79 (C-2),
131.02 (C-y), 131.46 (C-z), 131.96 (C-w), 143.82 (C-u),
150.18 (C-1), 174.14 (C-10), 174.34 (C-12); HRMS;
calcd for C23H28F3N3O6S: 532.1729. Found: 532.1743.
Benzyl 6-amino-caproate para-toluene sulfonate (18b). A
mixture of 6-aminocaproic acid (5 g, 38.11mmol), ben-
zyl alcohol (250mL) and para-toluene sulfonic acid
(8.38 g, 42.3mmol, 1.1 equiv) in benzene (500mL) was
heated at 100 C for 3 h (azeotropic distillation with a
Dean–Stark equipment). The solution was cooled to
20 C under argon atmosphere. After addition of ether
(500mL), the product was allowed to crystallize at
ÿ30 C, during 3 days. Filtration, washing with ether
and drying under vacuum gave 14.38 g (yield: 95%) of
salt 18b: mp 106–107 C; IR (KBr) n 3465, 2943, 2869,
3041, 1728, 1626, 1482, 1196, 1142 cmÿ1; 1H NMR
(CDCl3, 500MHz) d 1.19 (m, 2H), 1.48 (m, 4H), 2.20 (t,
J=7.3Hz, 2H), 2.31 (s, 3H), 2.74 (m, 2H), 5.04 (s, 2H),
7.16 (d, J=8.4Hz, 2H), 7.27–7.37 (m, 5H), 7.68 (br s,
3H), 7.72 (d, J=8.4Hz, 2H); 13C NMR (CDCl3,
125MHz) d 21.17, 24.02, 25.65, 26.92, 33.71, 39.55,
66.02, 125.74, 128.04, 128.09, 128.44, 128.97, 135.91,
140.76, 141.02, 173.01; MS (FAB+) m/e 222.
N,N0-Diterbutoxycarbonyl-3,5-dimethylpyrazole-1-carbox-
amidine (17). To a solution of 3,5-dimethylpyrazole-1-
carboxamidine nitrate (2 g, 9.74mmol) and di-t-butyl
dicarbonate (11.53mL, 10.96 g, 48.71mmol, 5 equiv) in
dry THF (80mL), was added, under argon atmosphere,
sodium hydride (90% purity, 1.23 g, 48.71mmol, 5
equiv). The mixture was stirred under reflux (80 C)
during 6 h. Ethanol was cautiously added dropwise, and
the solution was concentrated under vacuum. The resi-
due was dissolved in CH2Cl2 and washed with water.
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Drying over MgSO4, concentration and flash chroma-
tography gave 2.43 g (yield: 73%) of 17: mp 100–101 C;
IR (KBr) n 3322, 3111, 2937, 1761, 1694, 1656 cmÿ1; 1H
NMR (CDCl3, 500MHz) d 1.50 (s, 9H), 1.52 (s, 9H), 2.21
(s, 3H), 2.55 (s, 3H), 5.92 (s, 1H), 9.05 (br s, 1H); 13C
NMR (CDCl3, 125MHz) d 13.40, 15.09, 27.94, 80.49,
82.53, 111.24, 140.37, 144.00, 149.52, 150.32, 157.46; MS
(EI) m/e 338 (M), 282, 254, 238, 182, 165, 138, 96, 57, 43;
Anal. calcd for C16H26N4O4 (338.40): C, 56.78; H, 7.74;
N, 16.55. Found: C, 56.66; H, 7.76; N, 16.47.
Benzyl 6-(N,N0-diterbutoxycarbonyl)-guanidino-caproate
(19b). To a solution of 17 (2.5 g, 7.38mmol) in CH2Cl2
(300mL), were added 18b (3.19 g, 8.12mmol, 1.1 equiv)
and triethylamine (1.2mL, 873mg, 8.63mmol, 1.16
equiv) The mixture was stirred for 20 h at 20 C, then
washed successively with 1N HCl, water, 10% NaHCO3
and water (3). Drying (MgSO4), concentration and
chromatography on preparative MPLC gave 3.40 g
(yield: 98%) of 19b: Rf (SiO2; hexane:isopropanol,
2:1)=0.2; IR (KBr) n 3328, 2980, 1740, 1728, 1651,
1627, 1417, 1370, 1362, 1156 cmÿ1; 1H NMR (CDCl3,
500MHz) d 1.38 (m, 2H), 1.49 (s, 9H), 1.50 (s, 9H), 1.57
(m, 2H), 1.68 (m, 2H), 2.36 (t, J=7.3Hz, 2H), 3.39 (m, 2H),
5.11 (s, 2H), 7.20–7.40 (m, 5H), 8.30 (m, 1H), 11.50 (br
s, 1H); 13CNMR (CDCl3, 125MHz) d 24.51, 26.26, 27.98,
28.20, 28.62, 34.01, 40.58, 66.05, 79.11, 82.93, 128.10,
128.44, 135.95, 153.24, 156.02, 163.54, 173.21; MS (EI)
m/e 463, 351, 290, 202, 188, 161, 158, 145, 144, 130, 117,
108, 65; Anal. calcd for C24H37N3O6 (463.57): C, 62.18;
H, 8.04; N, 9.06. Found: C, 62.44; H, 8.21; N, 8.96.
6-(N,N0-Diterbutoxycarbonyl)-guanidino-caproyl chloride
(20b). A solution of 19b (2.9 g, 6.25mmol) in EtOH:
EtOAc (1:1; 50mL), placed in a Parr flask, was hydro-
genated (pH2=40 psi) in the presence of Palladium
catalyst (10% on C; 102mg, 0.957mmol, 0.153 equiv),
during 18 h at 20 C (vigorous shaking). Filtration,
concentration and drying under vacuum gave 2.21 g
(yield: 94%) of 6-(N,N0-diterbutoxycarbonyl)-guani-
dino-caproic acid: mp 83.1–84.1 C; 1H NMR (CDCl3,
500MHz) d 1.41 (m, 2H), 1.49 (s, 9H), 1.50 (s, 9H), 1.60
(m, 2H), 1.67 (m, 2H), 2.36 (t, J=7.3Hz, 2H), 3.43 (m,
2H), 8.40 (s, 1H), 11.50 (br s, 1H); 13C NMR (CDCl3,
125MHz) d 24.15, 26.11, 27.92, 28.12, 28.53, 33.64,
40.72, 79.51, 83.15, 153.12, 155.88, 162.88, 178.57; MS
(EI) m/e 373 (M), 317, 261, 244, 188, 161, 130, 57; Anal.
calcd for C17H31N3O6 (373.44): C, 54.67; H, 8.36; N,
11.25. Found: C, 54.75; H, 8.11; N, 10.81. A solution of
this acid (0.6 g, 1.6mmol) and thionyl chloride (0.6mL,
978mg, 8.22mmol, 5.12 equiv) in CH2Cl2 (20mL) was
refluxed (50 C) during 1.5 h, then concentrated under
vacuum. The excess of SOCl2 was removed by azeo-
tropic distillation with toluene (3) and CHCl3 (3).
The acid chloride 20b was dried under high vacuum
(617mg, 98% yield) and used without purification.
Biological evaluation (in solution)
The purity of the pepdidomimetics was controlled by
HPLC before use, with the following conditions: column:
Nucleosil C18, 5m, 25 cm; temperature: 25 C; eluent:
gradient from 20% CH3CN+0.015% TFAÿ80%
H2O+0.015% TFA to 80% CH3CN+0.015% TFA
ÿ20% H2O+0.015%; flow rate: 1mL/min; equipment:
Beckman, System Gold, 126 P Solvent module, 168
Detector (Analis, Belgium). The retention times (area)
were: 16b: t=5.43min (98.8%); 16a: t=7.53min
(96.9%); 12a: t=6.88min (100%); 13a: t=11.53min
(94.1%); 27: t=8.67min (98.5%).
The phosphate buered saline (PBS) solution (pH 7.3)
was prepared from NaCl (4 g), KCl (0.1 g), KH2PO4
(0.1 g) and Na2HPO4, 2H2O (0.71 g) dissolved in water
(HPLC grade, 500mL). The stock solutions of peptido-
mimetics contained 1 to 5mg of product per milliliter of
PBS buer; if needed, 0.5% DMSO could be added for
complete dissolution. The tested concentrations were
within 10ÿ6 to 10ÿ1M.
Blood was drawn from the antecubital vein of healthy
adult volunteers, who denied taking any medication for
the previous 15 days, into a plastic syringe containing
one part of 3.8% trisodium citrate to nine parts of
blood. Platelet rich plasma (PRP) was prepared by cen-
trifuging the blood at 1500 g for 10min at room tem-
perature. The PRP was drawn o and the remaining
blood was centrifuged at 6000 g for 20min at room
temperature to make platelet poor plasma (PPP). The PRP
was adjusted with PPP to a count of 3105 platelets/mL;
platelet count was measured with a Coulter counter.
400 mL of the PRP preparation and 50mL of the solution
of peptidomimetic to be tested, or saline, were pre-
incubated for 2min at 37 C in an aggregometer; 50mL
of 0.047mM ADP were added, and the aggregation was
monitored during 4min. Results were calculated as fol-
lows: [observed % aggregation (antagonist)] divided by
[maximum % aggregation (control)] equals the % of
control. The % inhibition=100ÿ% of control. Con-
centration–response curves were constructed and the
IC50 were determined as the concentration of antagonist
required to produce 50% inhibition of the response to
the agonist. At least two determinations were made for
each compound and the IC50 calculated by fitting to a
four parameter equation (average standard error of
30%).
Modelisation
All the degrees of freedom describing the molecular
geometry have been fully optimized at the approximate
quantum chemistry level AM1,61 using the minimization
procedures available in Gaussian suite of programs.62 In
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the structures superpositions, the starting point was the
fitting of the respective carboxyl functions.
Surface chemistry
The PET microporous membrane was manufactured by
Whatman SA (Louvain-la Neuve, Belgium) by track-
etching treatment of PET Mylar A film (Dupont de
Nemours, Brussels) characterized by a thickness of
12mm, a density of 1.39 g/cm3 (ASTM D 1505-66), a
melting point of 251 C (ASTM D 3418-82), a Mn of
48,800 and a MW of 88,800. The membrane contained
1.45106 pores/cm2 (apparent surface) of 0.49 mm in
diameter. For the surface modifications, disks of 13mm
in diameter were cut o the membrane; the open surface
of a disk sample is 3.01 cm2 (apparent surface and
internal surface of the pores).
The phosphate buer (pH 8.2) was prepared from
Na2HPO4.2H2O (4.215 g) and NaH2PO4.H2O (0.2065 g)
dissolved in water (250mL, HPLC grade). The MES
buer (pH 3.5) was obtained from 2-(N-morpholino)-
ethanesulfonic acid (MES, 5.331 g) dissolved in water
(250mL, HPLC grade). l-[4,5-3H] lysine mono-
hydrochloride in aqueaus solution was purchased from
Amersham (Little Chalfont, UK); the labeling solution
(10ÿ3M) was prepared as follows: to 250mL of un-
labeled lysine solution (0.1826 g/10mL phosphate buer)
were added 187.5mL of labeled lysine (as=98Ci/mmol);
this solution was diluted to 25mL with phosphate buf-
fer. Water (HPLC grade) was obtained with a Milli-Q
system (Millipore, Bedford, MA, USA).
Radioactivity measurement: the amount of labeled lysine
fixed on the PET disks was measured by liquid scintil-
lation counting (LSC) of the sample-associated radio-
activity according to references 7–9, using a Tri-Carb
1600 TR liquid scintillation analyser (PACKARD).
XPS analysis: the surface chemical composition of the
modified PET disks was determined by X-ray photo-
electron spectroscopy according to references 10 and
11 and 45-46, using a SSI-X probe (SSX-100/206)
spectrometer from Fisons (Surface Science Laboratories,
Mountain View, CA).
PET membrane oxidation. The PET disks (1 sample per
10mL of reactive solution) were immersed into an acidic
solution of KMnO4 (6 g, in 120mL of 1.2 N H2SO4),
and heated at 60 C during 1 h, under shaking with an
Edmund B hler stirrer (model KL-2). The PET disks
were taken o the solution with tweezers and washed
successively with 6N HCl (120min and 25min;
10mL per sample) and water (210min; 10mL per
sample). The disks were drained over filter paper and
air-dried. Oxidized PET is called PET- CO2H.
Activation of PET-CO2H. The PET-CO2H disks (1
sample per 20mL of reactive solution) were immersed
into a solution of 1-(3-dimethylaminopropyl)-3-ethyl-
carbodiimide hydrochloride (water soluble carbodi-
imide=WSC; 0.1 g) in 0.1N MES buer (100mL), for
1 h at 20 C, under shaking. The samples were taken o
the solution and rinsed successively with 0.1N MES
buer (110min; 20mL per sample) and water
(210min; 20mL per sample). The activated PET-
CO2H disks were directly used for the radiolabeling and
the coupling to the peptidomimetic.
Radiolabeling of PET-CO2H. The activated PET- CO2H
disks were individually treated in small pyrex tubes
containing 1.5mL of the radioactive lysine* solution
(10ÿ3M), during 2 h at 20 C, under shaking. The disks
were individually washed with 1.5mL of phosphate
buer (pH 8, 110min and 25min), 1.5mL of water
(15min), 1.5mL of 0.005M HCl (310min) and
1.5mL of water (15min and 25min). The samples
were drained over filter paper and directly used for the
radioactivity measurement; they were individually
placed in 20mL polyethylene vials containing 5mL of
aqualuma cocktail (Lumac, Basel, Switzerland). The
blank samples (references for the counting of the non-
specific fixation or adsorption of the radioactive label)
were prepared according to the previous procedures,
but, in the activation step, the carbodiimide was omitted.
LSC counting results (average of five dierent samples
standard deviation): sample: 57.53.8 pmol/cm2 of
open surface; blank: 22.92.9 pmol/cm2 of open surface;
corrected value: 34.63.3pmol/cm2 of open surface. Since
a PET interface domain of 50 A˚ in depth contains about
2860pmol of monomer units/cm2, the value of 35pmol/
cm2 corresponds to 1.22% of surface derivatization.7
Coupling of peptidomimetic to PET-CO2H. The acti-
vated PET-CO2H disks were individually treated in
small pyrex tubes containing 1.5mL of peptidomimetic
solution (30.9mg of 16b in 50mL of phosphate buer),
during 2 h at 20 C, under shaking. The disks were
individually washed as described for the radiolabelling,
then air-dried and storred in the dark.
The blank samples (references for the XPS analysis of
the peptidomimetic adsorption) were prepared accord-
ing to the previous procedures, but, in the activation
step, the carbodiimide was omitted.
XPS analysis results: sample: C1s, 70.86%; O1s 27.58%;
N1s, 1.32%; F1s, 0.24%; blank; C1s, 70.69%;O1s, 28.96%;
N1s, 0.35%; F1s, 0.00%. F/C  100 atomic ratio: sam-
ple: 0.339; blank: 0.000 (no correction needed). Calcu-
lation of the percentage of surface derivatization: we
considered a theoretical monomer unit consisting of
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[(PET)x+ (PETÿRGD peptidomimetic)y], i.e.
[(C10H8O4)x+ (C31H36O9N6F3)y], where x+y=1. Thus,
the F/C atomic ratio is 3x/[31x+10(1-x)]. For F/
C=0.00339 (experimental value), x=0.01079, i.e. 1.08%
of modified units.
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